|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.57 USD | -2.03% |
|
+0.04% | -11.18% |
| Dec. 10 | Arvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment | MT |
| Dec. 06 | Pfizer: to present its latest data to ASH and SABCS | CF |
| Capitalization | 145B 138B 128B 114B 205B 12,297B 227B 1,592B 588B 5,049B 544B 532B 22,035B | P/E ratio 2024 * |
15.9x | P/E ratio 2025 * | 11.9x |
|---|---|---|---|---|---|
| Enterprise value | 203B 193B 179B 159B 288B 17,240B 319B 2,231B 824B 7,079B 763B 746B 30,891B | EV / Sales 2024 * |
3.23x | EV / Sales 2025 * | 3.11x |
| Free-Float |
-
| Yield 2024 * |
6.51% | Yield 2025 * | 6.64% |
More valuation ratios
* Estimated data
More news
Last Transcript: Pfizer, Inc.
More recommendations
More press releases
| 1 day | +0.59% | ||
| 1 week | +0.04% | ||
| Current month | -2.44% | ||
| 1 month | -4.30% | ||
| 3 months | -14.02% | ||
| 6 months | -8.91% | ||
| Current year | -11.18% |
1 week
25.14
26.44
1 month
24.4826.85
Current year
24.4831.54
1 year
24.4831.54
3 years
24.4861.71
5 years
24.4861.71
10 years
24.4861.71
| Director | Title | Age | Since |
|---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 2018-12-31 |
David Denton
DFI | Director of Finance/CFO | 59 | 2022-05-01 |
Rady Johnson
CMP | Compliance Officer | 63 | 2013-11-30 |
| Manager | Title | Age | Since |
|---|---|---|---|
Suzanne Johnson
BRD | Director/Board Member | 66 | 2007-08-31 |
Helen Hobbs
BRD | Director/Board Member | 71 | 2011-12-11 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 2013-09-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.74% | 380 M€ | +10.44% | - | |
| 9.37% | 20 M€ | +16.10% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -2.03% | +0.04% | -11.15% | -51.55% | 148B | ||
| -0.50% | -1.69% | +33.70% | +227.51% | 724B | ||
| +0.03% | +0.03% | +17.04% | +108.39% | 491B | ||
| -0.25% | -2.05% | -3.36% | -9.83% | 360B | ||
| -0.51% | -3.21% | +17.68% | +40.01% | 312B | ||
| -2.69% | -0.83% | -2.65% | +39.08% | 263B | ||
| -1.32% | -0.28% | +0.20% | -32.68% | 236B | ||
| -1.78% | -2.58% | +3.85% | +28.30% | 212B | ||
| -0.69% | -4.58% | +4.77% | +18.89% | 204B | ||
| -0.68% | -0.92% | +2.46% | +30.76% | 149B | ||
| Average | -0.55% | -1.33% | +6.25% | +39.89% | 309.81B | |
| Weighted average by Cap. | -0.44% | -1.31% | +11.91% | +76.23% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 62.91B 59.88B 55.49B 49.36B 89.1B 5,339B 98.74B 691B 255B 2,192B 236B 231B 9,567B | 63.34B 60.29B 55.87B 49.69B 89.71B 5,375B 99.41B 696B 257B 2,207B 238B 233B 9,632B |
| Net income | 9.31B 8.86B 8.21B 7.3B 13.19B 790B 14.61B 102B 37.75B 324B 34.95B 34.2B 1,416B | 12.48B 11.88B 11.01B 9.79B 17.68B 1,059B 19.59B 137B 50.61B 435B 46.86B 45.85B 1,898B |
| Net Debt | 58.24B 55.43B 51.37B 45.69B 82.48B 4,943B 91.41B 640B 236B 2,029B 219B 214B 8,857B | 52.13B 49.62B 45.98B 40.9B 73.82B 4,424B 81.81B 573B 211B 1,816B 196B 191B 7,927B |
More financial data
* Estimated data
Employees
88,000
Sector
Pharmaceuticals
Calendar
2025-02-03
- Q4 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-10 | 25.57 $ | -2.03% | 43,256,395 |
| 24-12-09 | 26.10 $ | +1.44% | 37,464,823 |
| 24-12-06 | 25.73 $ | +0.12% | 31,830,727 |
| 24-12-05 | 25.70 $ | +1.86% | 43,647,885 |
| 24-12-04 | 25.23 $ | -1.29% | 42,541,528 |
Delayed Quote Nyse, December 10, 2024 at 04:00 pm EST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
25.57USD
Average target price
32.40USD
Spread / Average Target
+26.72%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PFE Stock